Mon premier blog

Polymorphism in the pharmaceutical industry Rolf Hilfiker
Publisher: Wiley-VCH

Screening for polymorphs is crucial for drug research and development, since the crystal form of the active pharmaceutical ingredient (API) directly correlates with its pharmacokinetic properties. The pharmaceutical industry (active ingredients and excipients). Its activities are based on the hypothesis that there is some The structure of the Consortium, now moving into its second phase, was informed by the SNP [single nucleotide polymorphism] Consortium, which Holden also organised and led. According to George Tranter from Chiralabs, “Crystallisation is one of the biggest problems of the pharmaceutical industry”. Pharmaceuticals companies are constantly battling the problem of polymorphism in which an active drug can actually exist in more than one form or crystal structure which can cause the drug to act in very different ways. Take any tiny hint that someone with a certain polymorphism responds badly to a particular drug, and industry will claim the gene is bad, not the drug. Another classic pharmacogenetic example is the study of thiopurine S-methyltransferase (TPMT, an enzyme which transfers methyl groups [CH3] to a sulphur-containing purine residue) genetic polymorphism (Figure 2A) (Weinshilboum and Sladek, 1980). Science, growing awareness of patients' needs, the hesitant but increasingly interested pharmaceutical industry, and government agencies are forging a movement towards personalization of drug treatments. In Japan developed a kind of anti-cancer drug named TS-1, including Tegafur, Gimeracil and Potassium Oxonate three kinds of composition. Abstract: The polymorphic stability of a drug substance is a very important topic in the pharmaceutical industry. Crystallization processes have been commonly used in the pharmaceutical industry to purify and generate APIs. That is, it is not a man-made invention but a property of each substance. Taiho Pharmaceutical Industry Co., Ltd. In February, Automotive was the most spammed industry sector with a spam rate of 84.3 percent. Pharma-IQ.com is a new online network and content resource designed exclusively for the pharmaceutical industry. Pharma-IQ.com serves the pharma and biotech community with complimentary access to an exclusive library of keeping them up-to-date with industry trends, technological developments and the regulatory landscape. Pharma IQ Events include: Cool Chain, Compound Management, Polymorphism & Crystallisation and Lean Six Sigma for Pharma. The Consortium brings together the Wellcome Trust, medicines regulators, academic researchers and representatives from ten multinational pharmaceutical companies.